At FDA's request, Type D Meeting expected in March 2026 to review Comparative Oncology biomarker data from patients treated in OST-HER2 Phase 2b human clinical trial and OST-HER2 trial in spontaneous ...

New Market Briefing From Black Book Research Highlights 80% of Surveyed Hospitals Active in EHR Initiatives and Accelerating Demand for SATUSEHAT Interoperability Operations LONDON, GB / ACCESS ...

Greetings and welcome to PolyPid's Fourth Quarter and Full Year 2025 Conference Call. [Operator Instructions] As a reminder, this call is recorded. And I would now like to introduce your host for ...

Request for FDA Rolling Review submitted to FDA on January 30, 2026 Non-Clinical and CMC BLA modules submitted to FDA At FDA's request, Type D Meeting expected in March 2026 to review Comparative ...

PolyPid reported a quarterly loss of $0.41 per share for Q4 2025, falling short of the expected loss of $0.33 per share. This resulted in a negative surprise of 24.24%, reflecting challenges in the ...

Questions? Learn more about RF Study Card Programs by contacting [email protected] and about card programs by contacting [email protected]. Contact Valerie Dennis, Director of ...

Our CVIS (Cardiovascular Information Management System) is a unique software solution that empowers you to improve the clinical and financial performance of your cardiology department. Clinical ...

1-Year Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate High Patient Survival with Low Morbidity 2-Year Data from the AMDS PERSEVERE IDE Trial Further Demonstrate the Persistent Clinical ...

Moreover, we discuss strategies for metadata selection and human evaluation to ensure the quality and effectiveness of ITDs. By integrating these elements, this tutorial provides a structured ...

The Centers for Medicare & Medicaid Services (CMS) is moving steadily toward the use of FHIR-based digital quality measures (dQMs). CMS believes dQMs will enable a more dynamic, interoperable, and ...

New York, New York--(Newsfile Corp. - February 2, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today ...